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Introduction
Inflammation is usually the consequence of tissue damage
and its purpose is to direct plasma factors and immune
cells to the lesion site to eradicate infection and repair
damaged tissue. In pathological conditions such as
chronic inflammation, infiltration of immune cells into the
target tissue precedes tissue damage; the lesion occurs
after infiltration of immune cells. Based on observations in
animal models it is usually thought that the first cells to
infiltrate the tissue are T lymphocytes (TL), suggesting a
pathogenic role for the latter cells. However, the mecha-
nisms underlying the extravasation of T cells into the joint
are still elusive [1]. T cell cytokines such as IL-4, IL-10,
IL-13, and transforming growth factor (TGF)-β have pre-
dominantly anti-inflammatory effects and, in the human
system, IFN-γ alone displays weak activation capacity in
terms of IL-1β and tumor necrosis factor (TNF)-α induc-
tion, suggesting that soluble factors produced by T cells
are not pathological mediators. Therefore, T cells might
exert a pathological effect through direct cellular contact
with monocyte-macrophages (Mφ). Studies carried out
during the past ten years in our laboratory proved the
premise that IL-1β and TNF-α are markedly increased in
this interaction [2–8]. This was further confirmed by others
[9–12]. This review aims to assess the importance of
contact-mediated monocyte activation by stimulated TL
resulting in cytokine production, and its relevance to
chronic inflammatory conditions as exemplified by rheuma-
toid arthritis (RA). Possible modulations and controls of
this mechanism are discussed.
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Chapter summary
Contact-mediated signaling of monocytes by human stimulated T lymphocytes (TL) is a potent
proinflammatory mechanism that triggers massive upregulation of the proinflammatory cytokines IL-1
and tumor necrosis factor-α. These two cytokines play an important part in chronic destructive
diseases, including rheumatoid arthritis. To date this cell–cell contact appears to be a major
endogenous mechanism to display such an activity in monocyte-macrophages. Since TL and
monocyte-macrophages play a pivotal part in the pathogenesis of chronic inflammatory diseases, we
investigated the possible ligands and counter-ligands involved in this cell–cell interaction. We also
characterized an inhibitory molecule interfering in this process, apolipoprotein A-I. This review aims to
summarize the state of the art and importance of contact-mediated monocyte activation by stimulated
TL in cytokine production in rheumatoid arthritis and mechanisms that might control it.
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Historical background
The history of contact-mediated activation of Mφ by stimu-
lated TL (reviewed in (13]) began in the mid-eighties when
it was observed that the expression of membrane-associ-
ated IL-1 (IL-1α) in mouse Mφ was mediated by both
soluble factors and direct contact with T cells. The impor-
tance of cellular contact was confirmed by experiments
showing that IL-1 was induced upon T cell-Mφ contact
with both Th1 and Th2 cells in the absence of lymphokine
release. We also observed that direct contact with stimu-
lated T cells was a potent stimulus of Mφ activation.
Although observations have shown that the induction of
murine Mφ effector functions mediated by TL in living cell
co-cultures involved signals delivered by cell–cell contact
together with IFN-γ, fixed, stimulated T cells induced TNF
production in Mφ in the absence of IFNγ. Furthermore,
when isolated plasma membranes from different stimu-
lated T-cell clones were used, both stimulated Th1 and
Th2 cells were able to activate Mφ, establishing that direct
contact with stimulated T cells was a potent mechanism
inducing Mφ effector functions.
Triggering of cytokine production in chronic
inflammation
Based on histology, function, animal models and clinical
studies, Mφ appear to play a key role in chronic inflamma-
tion by producing large amounts of IL-1 and TNF-α under
various stimuli. In chronic inflammation, infiltration of TL into
the target tissue precedes tissue damage suggesting that
their effect is pathogenic. Angiogenesis and proliferation
of resident cells accompany this infiltration. However, Mφ
are rapidly found in the lesion and interactions occur
between TL and Mφ. These interactions lead to IL-1 and
TNF-α production, a process that is potentiated by many
other factors including IFN-γ, IL-15, and IL-18; T cell
cytokines such as IL-4, IL-10, IL-13, and TGF-β are
inhibitory (Fig. 1). Our previous seminal studies and further
works by others strongly argue that direct cellular contact
with stimulated T cells is a major pathway for the produc-
tion of IL-1 and TNF-α in Mφ [13]. Indeed, contact-medi-
ated activation of Mφ by stimulated TL is as potent as
optimal doses of lipopolysaccharide (LPS) or phorbol
myristate acetate in inducing IL-1β and TNF-α production
in monocytes and cells of the monocytic lineage, such as
THP-1 cells [13]. We therefore postulate that this mecha-
nism is highly relevant to the pathogenesis and mainte-
nance of chronic inflammation in diseases such as RA.
Relevance of contact-mediated activation of
Mφ φ to chronic inflammatory diseases
Tlymphocytes are likely to play a pivotal role in the patho-
genesis of RA [1]. In RA, TL displaying a mature helper phe-
notype (i.e. CD3+ CD4+ CD45RO+) are the main infiltrating
cells in the pannus, at percentages ranging from 16% of
total cells in ‘transitional areas’ to 75% in ‘lymphocyte-rich
areas’ [14,15]. The latter are to be found in perivascular
regions, around ‘high endothelial venule’-like vessels,
where TL extravasation occurs forming germinal center-like
structures [16]. Although they are the most abundant infil-
trating cells in the pannus, the importance of TL in RA
pathogenesis has been mainly proven in animal models [1].
Indeed, T cells from RA patients that were transferred to
SCID mice induced arthritis [17]. Although evidence sug-
gests that TL play a pathogenic part in chronic inflammatory
diseases, the mechanism by which they exert their patho-
genicity has not been clearly elucidated [1], thus contact-
mediated induction of proinflammatory cytokines in Mφ
might represent one of these mechanisms.
T cell signaling of Mφ φ by direct cell–cell contact
The activation of effector cells mediated by stimulated TL
has been abundantly substantiated in the T-B lymphocyte
model for the induction of cell proliferation and antibody
secretion, which require both direct cell–cell contact and
soluble signals. Indeed, B cells can be activated in the
absence of antigen by direct contact with activated
T cells. A considerable amount of signaling crosstalk was
observed in T and B cells, that triggered various synchro-
nized signals resulting in the activation of effector func-
tions in both cell types, as recently exemplified in RA [18].
Similarly, ample data exist regarding the crosstalk
between dendritic cells and TL. However, much less is
known about the crosstalk between TL and Mφ, other than
antigen presentation.
Figure 1
Scheme of the activation cascade from T lymphocytes (TL) to
monocyte-macrophages (Mφ) and fibroblasts/synoviocytes (F/S).
Activated TL trigger Mφ to produce proinflammatory cytokines that in
turn induce the production of matrix-destructive metalloproteinases
(MMPs) and prostaglandin E2 (PGE2), the latter products being
involved in cartilage destruction and bone resorption. These processes
are controlled by proinflammatory factors (IL-15, IL-2, IL-18, IL-17) and
anti-inflammatory factors (IL-4, IL-10, granulocyte/macrophage colony
stimulating factor [GM-CSF], IFN-β). Furthermore, naturally occurring
inhibitors (IL-1sRII, IL-1Ra, tumor necrosis factor [TNF]sRI, TNFsRII)
inhibit the activity of IL-1 and TNF-α, the production of which is
blocked by apolipoprotein (apo) A-I and decreased by exogenous
antibodies to CD69 and β2-integrins (CD11b>CD11c>CD11a). 
APC, antigen presenting cells; DC, dendritic cells.S171
Most T cell types, including T cell clones, freshly isolated
TL, and T cell lines (such as HUT-78 cells) induce IL-1
and TNF-α in Mφ [2,3,5,13]. Various stimuli other than
phytohemagglutinin/phorbol myristate acetate induce TL
to activate monocytes by direct cellular contact: cross-
linking of CD3 by immobilized anti-CD3 mAb with or
without cross-linking of the co-stimulatory molecule
CD28 [7,12,19]; antigen recognition on antigen-specific
T cell clones [7]; and cytokines [9,10,20]. Furthermore,
depending on T cell type and T cell stimulus, direct
cell–cell contact with stimulated TL can induce different
patterns of products in Mφ (Table 1). This suggests that
multiple ligands and counter-ligands are involved in the
contact-mediated activation of Mφ, which are differentially
induced in T cells depending on the stimulus. Recent
studies by Brennan et al. [12] have led to the concept
that, based on their effect on Mφ, TL can be classified as
cytokine-activated TL (Tck) (which are likely to be present
in RA synovium [12]) or T-cell-receptor-activated TL. In
some cases, an imbalance in production of proinflamma-
tory versus anti-inflammatory cytokines has been
observed, where Th1 cell clones preferentially induce IL-
1β rather than IL-1Ra production, and cytokine-stimulated
TL induce TNF-α production but not that of IL-10 [7,9].
Besides, we demonstrated that upon contact with stimu-
lated T cells, the balance between IL-1β and IL-1Ra pro-
duction in monocytes is ruled by Ser/Thr phosphatase(s)
[8] and that contact-activated THP-1 cells express mem-
brane-associated protease(s), neutralizing TNF-α activity
both by degrading the latter cytokine and by cleaving its
receptors at the cell surface [6]. Thus triggering these
intra- and extra-cellular processes by direct contact with
stimulated TL may regulate the proinflammatory cytokines
and their inhibitors. The balance of their production in
monocytes dictates, in part, the outcome of the inflamma-
tory process, as depicted in Figure 1.
Cell surface molecules involved in contact-
mediated monocyte activation
A critical issue arising from these observations is the iden-
tity of the molecules on the T cell surface that are involved
in contact-mediated signaling of Mφ activation, as well as
their counter-ligands. It has been postulated that T cell
membrane-associated TNF-α was involved in Mφ activa-
tion. However, fixed, stimulated Th2 cells from a T cell line
that did not express membrane-associated TNF induced
both TNF and IL-1 production in Mφ [21] demonstrating
that TNF-α might play a part, but not a primary one. We
have shown that neither soluble TNF-α receptors nor
IL-1Ra block T cell signaling of the monocytic cell line
THP-1. Besides, neutralizing antibodies to TNF-α, IL-1,
IL-2, IFN-γ, and granulocyte/macrophage colony stimulat-
ing factor all failed to affect monocyte activation by mem-
branes from stimulated T cells [2–4]. Similarly, although
lymphotoxin (LT)-α receptor is expressed in Mφ, it is not
likely that membrane-associated LT is involved in Mφ sig-
naling upon contact with stimulated T cells, since Th2
cells do not express LT at either protein or mRNA levels. It
must be emphasized that the contact between TL and Mφ
could involve different ligands and counter-ligands in the
murine and the human systems.
In addition to membrane-associated cytokines, other
surface molecules have been assessed for their ability to
activate Mφ upon contact with stimulated T cells (e.g.
lymphocyte function-associated antigen [LFA]-1/intercel-
lular adhesion molcule-1, CD2/LFA 3, CD40/CD40L, and
lymphocyte activation antigen-3. Thus CD40/CD40L
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Table 1
Depending on T-cell stimulus, various products are induced in monocytes upon cell–cell contact
Stimulus Type of T cell Type of monocyte Products References
PHA/PMA PB TL, HUT-78 cells, Jurkat  PB monocytes, THP-1 cells TNF-α, IL-1β, IL-6, IL-8, IL-1α, [2–6,8,62]
cells, synovial and PB T cell  IL-1Ra, TNFsRs, MMP-1 
clones: CD4+; CD8+; Th1; and Th2 MMP-9, TIMP-1
PdBu/ionomycine PB TL PB monocytes TNF-α, IL-10 [19]
anti-CD3 PB TL, synovial T cells PB monocytes, THP-1 cells TNF-α, IL-10, IL-1β; MMP-1 [4,12,19,22,62]
anti-CD3 and anti-CD28  Th1 cell clones THP-1 cells IL-1β, low IL-1Ra [7]
or specific Ag
anti-CD3 and anti-CD28  Th2 cell clones THP-1 cells IL-1Ra, low IL-1β [7]
or specific Ag
Cytokines* PB TL, synovial T cells, Th1 and  PB monocytes TNF-α, IL-1β [9–12,20,63]
Th2 cell clones
Anti-CD3 PB TL PMA/IFN-γ-treated U937 cell TNF-α, IL-10, IL-12 and IL-4 [64]
*IL-2 or IL-15 alone or in combination with IL-6 and TNF-α. Ag, antigen; MMP, matrix metalloproteinase; PB, peripheral blood; 
PHA, phytohemagglutinin; PMA, phorbol myristate acetate; Th, T helper cell; TIMP, tissue inhibitor of matrix metalloproteinases; TL, T lymphocyte; 
TNF, tumor necrosis factor; TNFsRs, TNF soluble receptors. Modified and published with permission from European Cytokine Network [13].S172
interaction was shown to be involved in the contact activa-
tion of both human and mouse Mφ by TL stimulated for
6 hours [22]. However, when stimulated for 24 hours, TL
isolated from both CD40L knockout and wild type mice
triggered Mφ activation, although to a lesser extent [23]. In
our system, where human TL were stimulated for 48 hours
and expressed a high capacity to induce cytokines in Mφ,
we never observed any inhibition of contact-induced
cytokine production, by blocking antibodies to either
CD40L or soluble CD40. Furthermore, HUT-78 cells,
which efficiently induce cytokine production in Mφ, do not
express CD40L mRNA in resting or activated condition
[24]. Finally, THP-1 cells that respond to contact-medi-
ated activation by membranes of stimulated T cells do not
express CD40. Another study of ours shows that in co-
cultures of living cells stimulated with IL-15, Th1- but not
Th2-clones induce IL-1β production in monocytes [20]. In
the latter system, blockade of the CD40–CD40L interac-
tion results in inhibition of IL-1β production while IL-1Ra
induction is unaffected. This differential effect indicates
the selective relevance of CD40–CD40L engagement
upon monocyte activation by Th1 clones. However, the
levels of CD40L expression did not differ in Th1 and Th2
cell clones, implying that additional, unidentified mole-
cule(s) preferentially expressed by Th1 cells are involved
in their capacity to induce IL-1β. Therefore, CD40–CD40L
might be a cofactor in contact-mediated activation of Mφ
by stimulated TL. Lymphocyte activation gene (LAG)-3
might also be one of the latter factors since it is able to
synergize with low amounts of CD40L in inducing TNF-α
and IL-12 on monocyte-derived dendritic cells [11]. In our
system LAG-3 did not induce the production of IL-1β and
TNF-α (unpublished results). Others have found that
soluble CD23 induces cytokine production on monocytes
[25]. In monocytes, the counter-ligands of CD23 are
CD11b/CD18 and CD11c/CD18 rather than CD21. LFA-
1 (CD11a/CD18) and CD69 also contribute to the activa-
tion of human monocytic cells by stimulated T cells [2,26].
This was substantiated by a study showing that IL-15
induced synovial T cells from RA patients to activate the
production of TNF-α by Mφ. This effect was inhibited by
antibodies to CD69, LFA-1 and intracellular adhesion
molecule-1 [10].
Together these studies suggest that some known surface
molecules are indeed involved in T cell signaling of Mφ.
However, inhibitors (e.g. antibodies) of these molecules
fail to abolish monocyte activation altogether, suggesting
that the factor(s) required for T cell signaling of human
monocytes by direct contact remain(s) to be identified.
Intracellular pathways involved in cytokine
production by monocyte-macrophages upon
contact with stimulated T lymphocytes
Depending on the type of stimulus, different intracellular
pathways are used in Mφ for the production of the same
cytokine. Some stimuli (i.e. microbial products) can induce
the production of TNF-α, IL-1β, and IL-1Ra in human Mφ.
In other cases, IL-1Ra might be induced in the absence of
IL-1 induction, but from what is known at present, all stimuli
eliciting IL-1β production also trigger IL-1Ra production, at
least in Mφ. The tight control of proinflammatory cytokine
production is indeed a prerequisite to avoid a cascade of
events that could lead to uncontrolled inflammation. It is
also well known that the production of both IL-1β and TNF-
α is tightly regulated at several levels, including the dissoci-
ation between transcription and translation [27]. For
example, stimuli such as C5a, hypoxia, blood clotting, or
surface contact are not sufficient to provide a signal for
translation, despite a vigorous signal for transcription [28].
Consequently, some stimuli might provide signals for com-
plete cytokine gene transcription but no translational sig-
naling. IL-1β and TNF-α translation can be blocked by
pyridinyl-imidazol compounds that bind and inactivate the
mitogen-activated protein kinase p38 [28].
Lipopolysaccharide has been the most frequently used
stimulus for in vitro studies aimed at identifying transduc-
tion pathways underlying cytokine production in Mφ. Com-
ponents of the transduction pathways that are induced by
toll-like receptor 4 [29,30] and lead to the translocation of
nuclear factor (NF)-κB, AP-1, protein kinase C [31], and
p44/42 (extracellular signal-regulated kinase) [32] are all
likely to be also involved in cytokine gene induction by
other stimuli. Other components of transcription pathways
leading to cytokine synthesis have been identified after
signaling by engagement of cell surface molecules. The
engagement of CD45 leading to TNF-α production in
monocytes adopts a unique signaling pathway (phospho-
inositol-3 kinase [PI3-K]) and pathways shared with LPS
(NF-κB and p38 kinase). Furthermore, different products
induced by the same stimulus can depend on different sig-
naling pathways (e.g. PI3-K pathway selectively controls
IL-1Ra, and not IL-1β, in ‘septic’ leukocytes [33]).
Upon T-cell-contact-mediated activation of Mφ, different
pathways are involved in the induction of IL-10 or TNF-α
[34,35]. Interestingly, PI3-K is mainly involved in IL-10
induction whereas NF-κB is involved in TNF-α production,
suggesting that PI3-K is preferentially involved in path-
ways controlling the production of anti-inflammatory
factors. T cells activated by a different stimulus also
induce these two pathways [12]. Indeed, T cells that had
been activated for eight days using a cocktail of cytokines
and designated Tck induced TNF-α production in resting
monocytes in a cell-contact-dependent manner [12]. The
same results were obtained with RA synovial T cells, sug-
gesting that Tck resemble RA synovial joint T cells in terms
of contact-mediated cytokine induction in monocytes. In
this system, TNF-α production was abrogated by block-
ade of the transcription factor NF-κB but enhanced by
PI3-kinase inhibitors. Production of TNF-α, induced in
Arthritis Research    Vol 4 Suppl 3 Burger and DayerS173
monocytes by peripheral blood T cells that were stimu-
lated by crosslinked anti-CD3, was not affected by NF-κB
and was inhibited in the presence of PI3-kinase inhibitors.
The premise that Tck behave similarly to RA T cells further
confirms the importance of T cells in inducing TNF-α in
chronic inflammatory rheumatoid tissue. We recently
demonstrated that PI3-kinase might represent a check-
point signaling molecule favoring IL-1Ra synthesis over
that of IL-1β [36]. Furthermore, upon contact with stimu-
lated T cells, the balance between IL-1β and IL-1Ra pro-
duction in monocytes was also regulated by Ser/Thr
phosphatase(s) [8].
Modulation of contact-mediated activation of
monocyte-macrophages
Since the contact-mediated activation of Mφ is a major
pathway toward cytokine production, the modulation of
this mechanism (i.e. the blockade of IL-1 and TNF-α pro-
duction at the triggering level of contact-mediated activa-
tion) would be of therapeutic interest. We established that
therapeutic agents used in RA and multiple sclerosis (i.e.
leflunomide [37] and IFN-β [38,39], respectively) affect
the contact-mediated activation of monocytes. Lefluno-
mide inhibits the ability of stimulated TL to trigger IL-1β
production in monocytes, resulting in an enhancement of
the IL-1Ra/IL-1β molar ratio [40]. Similar results were
obtained with IFN-β. Indeed, upon contact-mediated acti-
vation of monocytes, IFN-β not only inhibited IL-1β and
TNF-α but it also stimulated IL-1Ra [41,42], due to the
fact that IFN-β interfered with the activation of both TL and
monocytes. However, surface molecules of TL that we
found to be involved in contact-signaling of monocytes
(i.e. TNF-α, CD25, CD69, CD18, CD11a, CD11b,
CD11c, CD40L, and LAG-3) were not modulated by IFN-
β or leflunomide, suggesting that other surface activators
on TL are involved in the contact-mediated activation of
monocytes by stimulated TL. While CD40–CD40 ligand
engagement is required, it may not be sufficient for human
Th1 cell induction of IL-2- or IL-15-driven, contact-depen-
dent IL-1β production by Mφ [20]. These effects are
similar to those observed in patients in vivo, suggesting
the occurrence of contact-mediated activation of mono-
cytes in vivo.
Identification of a specific inhibitor of T-cell
contact-mediated activation of monocyte-
macrophages
The inhibition of T cell signaling of monocytes might be
important because it would maintain a low level of mono-
cyte activation within the blood stream. We recently identi-
fied apolipoprotein (apo) A-I as being a specific inhibitor of
contact-mediated activation of monocytes [43]. These
results were further confirmed by using recombinant apo
A-I [42]. Apo A-I is a ‘negative acute-phase protein’ and
the main protein of high-density lipoproteins (HDL). Varia-
tions of apo A-I concentration were observed in several
inflammatory diseases [44]. In RA, the levels of circulating
apo A-I and HDL-cholesterol in untreated patients were
lower than in normal controls [45–47]. In contrast, apo A-I
was enhanced in synovial fluid of RA patients [48],
although its concentrations remained 10-fold lower in syn-
ovial fluid than in plasma. The elevation of apo A-I levels in
synovial fluid of RA patients was accompanied by an
enhancement in cholesterol, suggesting an infiltration of
HDL particles in the inflamed joint. This putative regulatory
mechanism might, however, be overcome by serum
amyloid A (SAA), a positive acute-phase protein, which is
not only produced in the liver but also in the RA synovium
[49]. Indeed SAA can displace apo A-I from HDL, and
HDL-associated SAA displays proinflammatory activity
[50]. Recently, it was shown that the inflammatory condi-
tion in juvenile RA was associated with hypo-high density
lipoproteinemia and a significant decrease in apo A-I con-
centration in patient plasma [51]. Furthermore, in collabo-
ration with B Bresnihan (Dublin, Ireland), we observed that
apo A-I was present in the perivascular region of RA syn-
ovium but not in normal tissue (manuscript in preparation).
In systemic lupus erythematosus, apo A-I plasma concen-
trations are diminished. This decrease is associated with
the presence of anti-apo A-I antibodies in 32% of patients
[52]. In patients with multiple sclerosis undergoing IFN-β
therapy, levels of apo A-I proved to be lower in a subgroup
of patients experiencing relapses and/or progression [53].
Furthermore, increasing evidence strongly supports the
contention that inflammatory responses are an integral
part of atherosclerosis [54]. Indeed, Mφ and TL are present
at all stages of lesion development, and the earliest lesion
(fatty streak) consists predominantly of Mφ and TL. In addi-
tion, transfer of CD4+ T cells aggravates atherosclerosis in
immunodeficient apo E knockout mice [55]. Therefore, TL-
signaling of monocytes may occur in atherosclerosis.
Gene transfer of apo A-I reduced atherosclerosis in
several mouse models [56]. This phenomenon has been
attributed to the function of HDL-associated apo A-I in
lipid metabolism and transport. However, the premise that
apo A-I inhibit contact-mediated activation of Mφ by TL
suggests that HDL has protective functions at several
levels in atherosclerosis, including cytokine production by
Mφ. Furthermore, the incidence of atherosclerotic heart
disease is higher in patients with systemic lupus erythe-
matosus and RA [57], in agreement with the inverse corre-
lation of the concentration of HDL with the incidence of
atherosclerosis.
With the exception of atherosclerosis, which had not been
considered a chronic inflammatory disease until recently,
and despite the scarcity of studies having dealt with the
levels of HDL in ‘classical’ chronic inflammatory diseases,
it seems that chronic inflammation is associated with low
levels of HDL-associated apo A-I. We thus hypothesize
that in these diseases, a vicious circle sets in, which is
responsible for the maintenance of inflammation (Fig. 2).
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The identification of HDL-associated apo A-I ligand(s) on
stimulated T cells might lead to the elucidation of the
mechanisms and molecules involved in T cell signaling of
monocytes. HDL-associated apo A-I has been shown to
bind specifically to a number of cell-surface molecules,
including HDL binding protein [58], scavenger receptor
B1, HDL binding protein-2, cubilin [59], ATP-binding cas-
sette A1 transporter [60], and a 95 kDa protein at the
surface of human fetal hepatocytes [61]. All these proteins
display a high molecular weight (≥80 kDa) and to date
have not been identified (not searched) on T cells. In con-
clusion, the identification of apo A-I as an important regu-
lator of TL–Mφ interaction sheds new light on the role of
HDL-associated apo A-I in innate and acquired immune
response, and could be extended to other diseases.
Dissociation of IL-1β β and IL-1Ra production 
in monocytes in contact with stimulated
T lymphocytes due to the presence of
HDL-associated apo A-I
Although HDL inhibited the production of TNF-α and IL-1β
in both peripheral blood monocytes and THP-1 cells, this
did not apply to IL-1Ra. Indeed, in peripheral blood
mononuclear cells that were stimulated by either phyto-
hemagglutinin or an antigen (tetanus toxoid), IL-1Ra pro-
duction was not significantly inhibited, contrasting with the
obvious inhibition of IL-1β and TNF-α production (Fig. 3).
Furthermore, this indicates that apo A-I was able to inhibit
contact-mediated Mφ activation when TL were stimulated
by either nonspecific stimuli or antigens.
Concluding remarks
To date, direct cell–cell contact with stimulated TL is the
main pathway triggering activation of Mφ in the absence of
infectious agents. The potency of this mechanism sug-
gests that it is a major pathway by which TL exert their
pathogenic effect in chronic inflammatory diseases of
autoimmune etiology. Many more investigations are
needed to identify the surface molecules (ligands and
counter-ligands) involved in this process. However, the
control of contact-mediated signaling of monocytes by
apo A-I might represent the first step toward developing
novel agents that interfere with the inflammatory response
induced by cell–cell contact, which leads to tissue
destruction in chronic inflammatory diseases.
Glossary of terms
apo = apolipoprotein; HDL = high-density lipoprotein;
LAG = lymphocyte activation gene; LFA = lymphocyte-
function-associated antigen; LT = lymphotoxin; PI3-K =
phosiphinositol-3 kinase; PMA = phorbol myristate
acetate; SAA = serum amyloid A; Tck = cytokine-activated
T lymphocyte; TL = T lymphocytes.
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Figure 2
Scheme of the relationship between chronic inflammation, acute-phase
proteins and homeostasis of cytokines. The liver produces both
apolipoprotein (apo) A-I and serum amyloid A (SAA). IL-1β and TNF-α
differentially regulate the production of acute-phase proteins by
increasing the production of SAA (a proinflammatory factor) and
decreasing that of apo A-I (an anti-inflammatory factor). The decreased
level of apo A-I results in a better activation of monocyte-macrophages
(Mφ) by direct contact with stimulated Tlymphocytes (sTL), enhancing
the production of IL-1 and TNF. The increased levels of SAA result in
the substitution of apo A-I by SAA on high-density lipoprotein (HDL),
and SAA–HDL further stimulates the production of cytokines by Mφ.
Figure 3
Apolipoprotein (apo) A-I does not significantly inhibit IL-1Ra production
in peripheral blood mononuclear cells (PBMC) stimulated by either
phytohemagglutinin (PHA) or tetanus toxoid (TT). 
Conditions: 0.4 × 106 cells/well/200 µl; 5 µg/ml polymyxin; 1 µg/ml
PHA; 10 µg/ml TT; 48 hour incubation for PHA, 72 hours for TT.S175
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